Melanoma vaccine - Bavarian Nordic

Drug Profile

Melanoma vaccine - Bavarian Nordic

Alternative Names: MVA - malignant melanoma; MVA-BN tyr

Latest Information Update: 15 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic; BN ImmunoTherapeutics
  • Developer Bavarian Nordic
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 15 Nov 2005 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
  • 22 Dec 2004 Preclinical trials in Malignant melanoma in USA (unspecified route)
  • 23 Aug 2002 Discontinued - Phase-II for Malignant melanoma in Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top